Viveve Medical Inc.
| NASDAQ: VIVE | Healthcare / Medical Devices & Instruments / USA |
| 0.1000 | 0 | 0.00 | Vol 265.43K | 1Y Perf -90.29% |
| Feb 3rd, 2023 14:55 DELAYED |
| BID | 0.00 | ASK | 0.00 | ||
| Open | 0.1000 | Previous Close | 0.1000 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 6.25 | Analyst Rating | — 0.00 | |
| Potential % | 6.15K | Finscreener Ranking | ★★★★ — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ☆ 28.07 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ☆ 26.83 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 0.78 | Earnings Rating | Neutral | |
| Market Cap | 1.07M | Earnings Date | 16th Mar 2023 | |
| Alpha | -0.11 | Standard Deviation | 0.23 | |
| Beta | 0.60 |
Today's Price Range 0.09950.1150 | 52W Range 0.09101.24 | 5 Year PE Ratio Range -1.70-0.1000 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -16.67% | ||
| 1 Month | -84.00% | ||
| 3 Months | -81.98% | ||
| 6 Months | -86.15% | ||
| 1 Year | -90.29% | ||
| 3 Years | -99.04% | ||
| 5 Years | -100.00% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -288.65 | |||
ROE last 12 Months | -261.13 | |||
ROA (5Y Avg) | -65.57 | |||
ROA last 12 Months | -132.28 | |||
ROC (5Y Avg) | -100.88 | |||
ROC last 12 Months | -195.51 | |||
Return on invested Capital Q | -66.87 | |||
Return on invested Capital Y | -31.72 | |||
Assets Turnover | 0.10 | |||
Receivables Turnover | 3.50 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.20 | ||||
| 5.98 | ||||
| 1.43 | ||||
| - | ||||
| -0.50 | ||||
| -1.52 | ||||
| 5.98 | ||||
| 0.11 | ||||
| 7.05M | ||||
| Forward PE | -0.07 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.60 | ||||
| 0.90 | ||||
| 0.25 | ||||
| 4.97 | ||||
| -19.70 | ||||
| Leverage Ratio | 2.90 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 16.40 | ||||
| -311.00 | ||||
| -299.20 | ||||
| -381.20 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 5.12M | ||||
| 0.48 | ||||
| -21.33 | ||||
| -15.57 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2022 | - | -0.59 | - |
| Q02 2022 | - | -0.67 | - |
| Q01 2022 | - | -0.67 | - |
| Q04 2021 | - | -0.72 | - |
| Q03 2021 | - | -0.67 | - |
| Q02 2021 | - | -0.49 | - |
| Q01 2021 | - | -0.80 | - |
| Q03 2020 | - | -2.60 | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2019 QR | -16.00 | 4.02 | Positive |
| 12/2019 QR | -16.00 | 4.02 | Positive |
| 12/2022 FY | -2.55 | 3.04 | Positive |
| 12/2023 FY | -1.60 | 3.03 | Positive |
| Next Report Date | 16th Mar 2023 |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 265.43K |
| Shares Outstanding | 10.72K |
| Shares Float | 10.64M |
| Trades Count | 59 |
| Dollar Volume | 28.18K |
| Avg. Volume | 409.34K |
| Avg. Weekly Volume | 132.81K |
| Avg. Monthly Volume | 779.38K |
| Avg. Quarterly Volume | 315.82K |
Viveve Medical Inc. (NASDAQ: VIVE) stock closed at 0.1 per share at the end of the most recent trading day (a 0% change compared to the prior day closing price) with a volume of 265.43K shares and market capitalization of 1.07M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 55 people. Viveve Medical Inc. CEO is Scott C. Durbin.
The one-year performance of Viveve Medical Inc. stock is -90.29%, while year-to-date (YTD) performance is -76.47%. VIVE stock has a five-year performance of -100%. Its 52-week range is between 0.091 and 1.24, which gives VIVE stock a 52-week price range ratio of 0.78%
Viveve Medical Inc. currently has a PE ratio of -0.20, a price-to-book (PB) ratio of 5.98, a price-to-sale (PS) ratio of 1.43, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -132.28%, a ROC of -195.51% and a ROE of -261.13%. The company’s profit margin is -%, its EBITDA margin is -299.20%, and its revenue ttm is $5.12 Million , which makes it $0.48 revenue per share.
Of the last four earnings reports from Viveve Medical Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Viveve Medical Inc.’s next earnings report date is 16th Mar 2023.
The consensus rating of Wall Street analysts for Viveve Medical Inc. is — (0), with a target price of $6.25, which is +6 150.00% compared to the current price. The earnings rating for Viveve Medical Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Viveve Medical Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Viveve Medical Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 19.63, ATR14 : 0.07, CCI20 : -55.91, Chaikin Money Flow : -0.14, MACD : -0.11, Money Flow Index : 2.31, ROC : -54.57, RSI : 31.95, STOCH (14,3) : 4.76, STOCH RSI : 0.00, UO : 25.94, Williams %R : -95.24), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Viveve Medical Inc. in the last 12-months were:
Viveve Medical Inc.
Viveve Medical Inc designs, develops, manufactures, and markets medical devices for the non-invasive treatment of vaginal laxity. The company offers Geneveve, a non-invasive solution that includes the Viveve System, a radio frequency generator; a reusable hand piece and single-use treatment tip; and other consumable accessories. The Geneveve is indicated for use in general procedures for electrocoagulation and hemostasis in the US. The firm markets its products through sales employees and distributors in Asia, Europe, the Middle East, Latin America, the United States, Canada, and internationally.
CEO: Scott C. Durbin
Telephone: +1 720 696-8100
Address: 345 Inverness Drive South, Englewood 80112, CO, US
Number of employees: 55
